Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults by Coughlan, L, Sridhar, S, Payne, R, Edmans, E, Milicic, A, Venkatraman, N, Lugonja, B, Clifton, L, Qi, C, McMichael, A, Folegatti, PM, Lawrie, AM, Roberts, R, de Graaf, H, Sukhtankar, P, Faust, SN, Lewis, DJM, Lambe, T, Hill, AVS, Gilbert, SC

High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant by Venkatraman, N, Bowyer, G, Edwards, NJ, Griffiths, O, Powlson, J, Silman, D, Morter, R, Folegatti, PM, Minassian, AM, Poulton, ID, Collins, K, Brod, F, Angell-Manning, P, Berrie, E, Brendish, N, Glenn, G, Fries, L, Baum, J, Blagborough, AM, Roberts, R, Lawrie, AM, Lewis, DJ, Faust, SN, Gilbert, S, Ewer, KJ, Hill, AV

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: safety and parasite growth dynamics by Salkeld, J, Themistocleous, Y, Barrett, JR, Mitton, CH, Rawlinson, TA, Payne, RO, Hou, MM, Khozoee, B, Edwards, NJ, Nielsen, CM, Sandoval, DM, Bach, FA, Nahrendorf, W, Ramon, RL, Baker, M, Ramos-Lopez, F, Folegatti, PM, Quinkert, D, Ellis, KJ, Poulton, ID, Lawrie, AM, Cho, J-S, Nugent, FL, Spence, PJ, Silk, SE, Draper, SJ, Minassian, AM

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial by de Graaf, H, Payne, RO, Taylor, I, Miura, K, Long, CA, Elias, SC, Zaric, M, Minassian, AM, Silk, SE, Li, L, Poulton, ID, Baker, M, Draper, SJ, Gbesemete, D, Brendish, NJ, Martins, F, Marini, A, Mekhaiel, D, Edwards, NJ, Roberts, R, Vekemans, J, Moyle, S, Faust, SN, Berrie, E, Lawrie, AM, Hill, F, Hill, AVS, Biswas, S

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals by Hodgson, SH, Ewer, KJ, Bliss, CM, Edwards, NJ, Rampling, T, Anagnostou, NA, De Barra, E, Havelock, T, Bowyer, G, Poulton, ID, De Cassan, S, Longley, R, Illingworth, JJ, Douglas, AD, Mange, PB, Collins, KA, Roberts, R, Gerry, S, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Sinden, RE, Gilbert, SC, Bejon, P, Lawrie, AM, Nicosia, A, Faust, SN, Hill, AV

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial by Minassian, AM, Silk, SE, Poulton, ID, Mitton, CH, Jin, J, Diouf, A, Querol-Rubiera, A, Bisnauthsing, K, Ogrina, T, Payne, RO, Folegatti, P, Silman, D, Batra, R, Brendish, N, Taylor, IJ, Smith, R, Berrie, E, Morelle, D, Lievens, M, Noe, AR, Soisson, LA, Ashfield, R, Long, CA, Goodman, AL, Faust, SN, Nugent, FL, Lawrie, AM, Draper, SJ

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-... by Rampling, T, Ewer, KJ, Bowyer, G, Bliss, CM, Edwards, NJ, Wright, D, Payne, RO, Venkatraman, N, de Barra, E, Snudden, CM, Poulton, ID, de Graaf, H, Sukhtankar, P, Roberts, R, Ivinson, K, Weltzin, R, Rajkumar, BY, Wille-Reece, U, Lee, CK, Ockenhouse, CF, Sinden, RE, Gerry, S, Lawrie, AM, Vekemans, J, Morelle, D, Lievens, M, Ballou, RW, Cooke, GS, Faust, SN, Gilbert, S, Hill, AV

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults by Silk, SE, Kalinga, WF, Mtaka, IM, Lilolime, NS, Mpina, M, Milando, F, Ahmed, S, Diouf, A, Mkwepu, F, Simon, B, Athumani, T, Rashid, M, Mohammed, L, Lweno, O, Ali, AM, Nyaulingo, G, Mwalimu, B, Mswata, S, Mwamlima, TG, Barrett, JR, Wang, LT, Themistocleous, Y, King, LDW, Hodgson, SH, Payne, RO, Nielsen, CM, Lawrie, AM, Nugent, FL, Cho, J-S, Long, CA, Miura, K, Draper, SJ, Minassian, AM, Olotu, AI

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection by Hou, M, Barrett, JR, Themistocleous, Y, Rawlinson, TA, Diouf, A, Martinez, FJ, Nielsen, CM, Lias, AM, King, LDW, Edwards, NJ, Greenwood, NM, Kingham, L, Poulton, I, Khozoee, B, Goh, C, Hodgson, SH, Mac lochlainn, D, Salkeld, J, Guillotte-Blisnick, M, Huon, C, Mohring, F, Reimer, JM, Chauhan, VS, Biswas, S, Lawrie, AM, Silk, SE, Minassian, AM, Draper, SJ, Mukherjee, P, Taylor, IJ, Cho, J, Nugent, FL, Long, CA, Moon, RW, Miura, K, Chitnis, CE

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial by Silk, SE, Kalinga, WF, Salkeld, J, Mtaka, IM, Ahmed, S, Milando, F, Diouf, A, Bundi, CK, Balige, N, Hassan, O, Mkindi, CG, Rwezaula, S, Athumani, T, Mswata, S, Lilolime, NS, Simon, B, Msami, H, Mohamed, M, David, DM, Mohammed, L, Nyaulingo, G, Mwalimu, B, Juma, O, Mwamlima, TG, Sasamalo, IA, Mkumbange, RP, Kamage, JJ, Barrett, JR, King, LDW, Hou, MM, Pulido, D, Carnrot, C, Lawrie, AM, Cowan, RE, Nugent, FL, Roberts, R, Cho, J-S, Long, CA, Nielsen, CM, Miura, K, Draper, SJ, Olotu, AI, Minassian, AM

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. by Payne, RO, Silk, SE, Elias, SC, Miura, K, Diouf, A, Galaway, F, de Graaf, H, Brendish, NJ, Poulton, ID, Griffiths, OJ, Edwards, NJ, Jin, J, Labbé, GM, Alanine, DGW, Siani, L, Di Marco, S, Roberts, R, Green, N, Berrie, EE, Ishizuka, AS, Nielsen, CN, Bardelli, M, Partey, FD, Ofori, MF, Barfod, L, Wambua, J, Murungi, LM, Osier, FH, Biswas, S, McCarthy, JS, Minassian, AM, Ashfield, R, Viebig, NK, Nugent, FL, Douglas, AD, Vekemans, J, Wright, GJ, Faust, SN, Hill, AV, Long, CA, Lawrie, AM, Draper, SJ

Controlled human malaria infection with a clone of Plasmodium vivax with high quality genome assembly by Minassian, AM, Themistocleous, Y, Silk, SE, Barrett, JR, Kemp, A, Quinkert, D, Nielsen, CM, Edwards, NJ, Rawlinson, TA, Ramos Lopez, F, Roobsoong, W, Ellis, KJ, Cho, J-S, Aunin, E, Otto, TD, Reid, AJ, Bach, FA, Labbé, GM, Poulton, ID, Marini, A, Zaric, M, Mulatier, M, Lopez Ramon, R, Baker, M, Mitton, CH, Sousa, JC, Rachaphaew, N, Kumpitak, C, Maneechai, N, Suansomjit, C, Piteekan, T, Hou, MM, Khozoee, B, McHugh, K, Roberts, DJ, Lawrie, AM, Blagborough, AM, Nugent, FL, Taylor, IJ, Johnson, KJ, Spence, PJ, Sattabongkot, J, Biswas, S, Rayner, JC, Draper, SJ

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK by Voysey, M, Clemens, SAC, Madhi, SA, Weckx, LY, Folegatti, PM, Aley, PK, Angus, B, Baillie, VL, Barnabas, SL, Bhorat, QE, Bibi, S, Briner, C, Cicconi, P, Collins, AM, Colin-Jones, R, Cutland, CL, Darton, TC, Dheda, K, Duncan, CJA, Emary, KRW, Ewer, KJ, Fairlie, L, Faust, SN, Feng, S, Ferreira, DM, Finn, A, Goodman, AL, Green, CM, Green, CA, Heath, PT, Hill, C, Hill, H, Hirsch, I, Hodgson, SHC, Izu, A, Jackson, S, Jenkin, D, Joe, CCD, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, AM, Lelliott, A, Libri, V, Lillie, PJ, Mallory, R, Mendes, AVA, Milan, EP, Minassian, AM, Lambe, T, Pollard, AJ

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses by Barrett, J, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD, Green, CM, Hill, AVS, Lambe, T, Pollard, AJ

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial by Ramasamy, MN, Minassian, AM, Ewer, KJ, Flaxman, AL, Folegatti, PM, Owens, DR, Voysey, M, Aley, PK, Angus, B, Babbage, G, Belij-Rammerstorfer, S, Berry, L, Bibi, S, Bittaye, M, Cathie, K, Chappell, H, Charlton, S, Cicconi, P, Clutterbuck, EA, Colin-Jones, R, Dold, C, Emary, KRW, Fedosyuk, S, Fuskova, M, Gbesemete, D, Green, C, Hallis, B, Hou, MM, Jenkin, D, Joe, CCD, Kelly, EJ, Kerridge, S, Lawrie, AM, Lelliott, A, Lwin, MN, Makinson, R, Marchevsky, NG, Mujadidi, Y, Munro, APS, Pacurar, M, Plested, E, Rand, J, Rawlinson, T, Rhead, S, Robinson, H, Ritchie, AJ, Ross-Russell, AL, Saich, S, Singh, N, Pollard, AJ, Oxford COVID Vaccine Trial Group

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination by Minassian, AM, Silk, SE, Barrett, JR, Nielsen, CM, Miura, K, Diouf, A, Loos, C, Fallon, JK, Michell, AR, White, MT, Edwards, NJ, Poulton, ID, Mitton, CH, Payne, RO, Marks, M, Maxwell-Scott, H, Querol-Rubiera, A, Bisnauthsing, K, Batra, R, Ogrina, T, Brendish, NJ, Themistocleous, Y, Rawlinson, TA, Ellis, KJ, Quinkert, D, Baker, M, Lopez Ramon, R, Ramos Lopez, F, Barfod, L, Folegatti, PM, Silman, D, Datoo, M, Taylor, IJ, Jin, J, Pulido, D, Douglas, AD, de Jongh, WA, Smith, R, Berrie, E, Noe, AR, Diggs, CL, Soisson, LA, Ashfield, R, Faust, SN, Goodman, AL, Lawrie, AM, Nugent, FL, Alter, G, Long, CA, Draper, SJ